Skip to main content

Advertisement

Table 2 Hazard ratios of mortality according to baseline variables in HIV-infected patients starting ART in Tanzania

From: Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania

  Unadjusted Adjusteda
Baseline variables HR (95% CI) P HR (95% CI) P
Gender (male vs. female) 1.73 (1.15–2.61) 0.009 1.60 (1.00–2.57) 0.053
WHO stage (IV vs. I–III) 2.71 (1.64–4.49) <0.001 1.46 (0.81–2.65) 0.210
ART start year (vs. 2003–04)     
   2005 0.55 (0.35–0.87) 0.010 0.64 (0.38–1.08) 0.091
   2006 0.30 (0.17–0.56) <0.001 0.40 (0.19–0.83) 0.014
BMI (vs. ≥ 18.5 kg/m2)     
   <16 4.17 (2.29–7.60) <0.001 2.12 (1.06–4.24) 0.034
   16–18.4 1.60 (0.82–3.10) 0.168 1.27 (0.62–2.61) 0.516
Hemoglobin (vs. ≥ 12 g/dL for women and ≥ 13 for men)     
   <8 22.7 (5.40–95.7) <0.001 9.20 (2.05–41.3) 0.004
   8–9.9 13.5 (3.28–55.9) <0.001 7.50 (1.77–31.9) 0.006
   10–11.9 (10–12.9 for men) 6.21 (1.46–26.5) 0.014 4.03 (0.93–17.5) 0.063
TLC (vs. ≥ 1.2 × 109/L)     
   <0.6 3.58 (2.05–6.24) <0.001 1.72 (0.87–3.39) 0.117
   0.6–1.1 1.10 (0.69–1.74) 0.699 0.79 (0.48–1.32) 0.371
Platelet count (<150 vs. ≥ 150 × 109/L) 2.23 (1.40–3.57) 0.001 2.30 (1.33–3.99) 0.003
  1. aCox proportional hazards model adjusted for all variables listed in the table.
  2. HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count.